Japan Patent Office

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Retrieved on: 
Monday, March 11, 2024
Therapy, European Patent Office, UBC, University, Patent, University of British Columbia, IP Australia, PMN, Japan Patent Office, PROMIS, Patient, Neuroscience

The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.

Key Points: 
  • The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.
  • Protection for the immunogenic compositions of matter has also been obtained in Japan, Korea, India and Australia.
  • Further, patent applications were also recently allowed in the U.S. and Japan for two other Aβ targets.
  • “We are building a fortress of intellectual property protection around our novel approach to targeting toxic misfolded proteins to treat neurodegenerative diseases and these newly allowed patents validate that innovation in important geographies around the world,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Retrieved on: 
Monday, November 6, 2023
Adenosine deaminase, ADAR, Patent, RNA, Adenosine, Intellectual property, Oligonucleotide, ProQR, RNA editing, European Patent Office, United States Patent and Trademark Office, Inosine, Therapy, European Patent Convention, IP, General counsel, Japan Patent Office, 3D printing, Vaccine

“The new patent that the USPTO granted to ProQR further expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR.

Key Points: 
  • “The new patent that the USPTO granted to ProQR further expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR.
  • Our leading intellectual property portfolio protects our Axiomer® ADAR-mediated RNA editing platform technology and more fundamentally the use of an oligonucleotide to recruit endogenous deaminating enzymes in the cell,” said René Beukema, Chief Corporate Development Officer and General Counsel.
  • Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that makes RNA editing with oligonucleotides that recruit endogenous ADAR proprietary to ProQR.
  • Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.

RecycLiCo Battery Materials Secures Two Additional Patents in Japan and Australia for Battery Recycling

Retrieved on: 
Thursday, October 5, 2023
Benchmark, Lithium, Patent, ID4, Knowledge, Recycling, Benchmark Mineral Intelligence, Graphite, Intellectual property, Aluminium, Carbon, Manganese, Growth, AMY, Japan Patent Office, FSE, Cobalt, Nickel

The two patents issued bring RecycLiCo’s patent portfolio to ten granted patents and an additional six applications for battery recycling around the globe.

Key Points: 
  • The two patents issued bring RecycLiCo’s patent portfolio to ten granted patents and an additional six applications for battery recycling around the globe.
  • This underscores the vital need for the RecycLiCo process to handle both battery production scrap and black mass material.
  • This manufacturing process can result in off-spec cathodes that are scrapped as waste, which the RecycLiCo™ process can treat to produce high-quality cathode materials for battery re-manufacturing.
  • “We are pleased to add these patents to our portfolio as we continue to build on commercial partnerships that use our novel process,” said Zarko Meseldzija, CEO of RecycLiCo Battery Materials.

Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 17, 2023
BioNTech, KRAS, Antigen, Partnership, Planegg, CET, Q&A, Preferential motor reinnervation, Head, Corporate communication, CRADA, Clinical trial, National Cancer Institute, American Academy, FSE, IP, PRAME, TCR, EUR, Development, Cooperative research and development agreement, Melanoma, MD, Patient, Patent, Annual general meeting, Webcast, Japan Patent Office, Senior, R, Annual report, IND, Kirsten, Vaccine

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial and operational results for the six months ended June 30, 2023.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial and operational results for the six months ended June 30, 2023.
  • “In the first half of 2023, we have accomplished many significant milestones, and made substantial progress towards our strategic objectives”, said Selwyn Ho, Chief Executive Officer at Medigene.
  • “We advanced our IND / CTA enabling work on MDG1015 and expanded our pipeline into neoantigens targeting multiple KRAS mutations and HLAs in solid tumors.
  • The Executive Management Board, therefore, maintains its guidance for the fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, August 9, 2023
BCDA, DSMB, Survival, Stem cell, Data monitoring committee, Protein, Data analysis, Patent, Patient, Update, Heart, Maintenance, Therapy, Heart failure, Culture, Consultant, Facial muscles, MSC, Japan Patent Office, Security (finance), Phase, FDA, IND, Safety, Opposition procedure before the European Patent Office, Pharmaceuticals and Medical Devices Agency, Cell, IRB, PMDA, White lung, FS, Research, Breakthrough, Quality of life, Data collection, COVID, Microsoft Exchange Server, Trial of the century, MRI, European Patent Convention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Food, Pharmaceutical industry, Medical device, Cryptocurrency, Helix, NYHA

SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.

Key Points: 
  • SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • On July 12, 2023, the planned Data Safety Monitoring Board (DSMB) meeting was held utilizing the adaptive statistical analysis plan reviewed by FDA in the second quarter.
  • Second Quarter 2023 Financial Results:
    Revenues were approximately $43,000 for the three months ended June 2023, compared to approximately $974,000 in the three months ended June 2022, due primarily to the timing of collaboration agreement revenues.

Microbot Medical Expand IP protection in Japan

Retrieved on: 
Thursday, June 22, 2023
Patent, ZEUS robotic surgical system, IP, Patient, Japan Patent Office, Design patent, 3D printing

HINGHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY Robotic Surgical System.

Key Points: 
  • HINGHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY Robotic Surgical System.
  • Microbot’s IP portfolio for LIBERTY and its related technologies includes 19 patents issued/allowed and 41 applications pending.
  • This Design Patent complements previously received protection in Japan covering the unique design of the LIBERTY Robotic System remote controller.
  • Noa Ofer, Senior Director of IP, said, "We are thrilled to receive additional validation and protection for our LIBERTY Robotic Surgical System.

BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

Retrieved on: 
Thursday, June 8, 2023
Heart, Patent, Therapy, Heart failure, BCDA, DSMB, Patient, Japan Patent Office, Pharmaceutical industry, Medical device, Helix

This patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber.

Key Points: 
  • This patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber.
  • “Our Helix™ minimally invasive biotherapeutic delivery platform enables the successful development of cell and gene-based therapies for the heart,” said Dr. Peter Altman, BioCardia CEO.
  • This recent patent issuance provides additional protection to our technology and product offerings in Japan.
  • Developers of cardiac cell-based therapies, including BioCardia, are seeking first approvals to begin marketing for the treatment of heart failure in Japan.

Medigene AG Expands Patent Portfolio for its End-to-End Platform

Retrieved on: 
Monday, May 22, 2023
Preferential motor reinnervation, FSE, IP, PRAME, TCR, Melanoma, Patent, Antigen, Japan Patent Office, Pharmaceutical industry

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.
  • Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.
  • “We are delighted with the receipt of the patent grant for our PD1-41BB costimulatory switch receptor from the Japan Patent Office as it represents a further milestone as we continue to expand and strengthen our IP portfolio worldwide," said Selwyn Ho, CEO at Medigene.
  • The patent grant in China complements patent protection for PRAME already received in Eurasia, Japan and Korea.

CV Sciences, Inc. Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
ERC, CARES Act, Nicotine, OTCQB, PDT, Minimum daily balance, Japan Patent Office, Sale, Softgel, EBITDA, Acquisition, Patent, SAN, Growth, Relaxation, RSU, Pharmaceutical industry, Video game, Retail, CBD

SAN DIEGO, May 15, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.

Key Points: 
  • SAN DIEGO, May 15, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.
  • "Our first quarter gross margins exceeded our expectations and we are encouraged by improvements we have made to reduce operating expense.
  • Sales for first quarter 2023 were $4.1 million, a decrease of 7% from $4.4 million for the first quarter 2022.
  • The Company had negative adjusted EBITDA for the first quarter of 2023 of $0.2 million, compared to negative adjusted EBITDA of $2.5 million in the first quarter of 2022.

CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction

Retrieved on: 
Thursday, March 23, 2023
Nicotine, OTCQB, JPO, Patent, Patient, SAN, CBD, Japan Patent Office, FDA, Smoking, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

SAN DIEGO, March 23, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate of Grant from the Japan Patent Office (JPO) for its patent application 7216697.

Key Points: 
  • The patent covers methods of treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine.
  • "The worldwide market for smokeless tobacco addiction is a multi-billion dollar sector, providing a life-changing treatment to people around the world," said Joseph Dowling, CEO of CV Sciences.
  • "CV Sciences' developmental efforts surrounding CBD and nicotine have the potential to alter healthcare with a safe, natural method to reducing addiction to harmful substances.
  • CV Sciences' initial drug candidate (CVSI-007) contains nicotine and CBD to support the cessation of smokeless tobacco use and addiction.